ImmunityBio, Inc. (IBRX) shares surged 5.19% in pre-market trading on Tuesday, showing significant investor interest ahead of the regular session.
The sharp rise appears to be driven by positive analyst sentiment, with HC Wainwright & Co. maintaining its Buy rating on the biopharmaceutical company. Analyst ratings often serve as key catalysts for stock movements, particularly when established firms reaffirm bullish positions on companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.